Merck (MRK) Insider Coe Mary Ellen Buys $30K of Stock
Mary Ellen Coe buys 234 shares of Merck, highlighting insider interest.
Reviewed by automated data checks against the source filing. How we make and check alerts
Coe Mary Ellen bought 234 shares of Merck & Co., Inc. ($MRK) at an average price of $128.50, worth about $30,069, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MRK is up 0.3% after 1 week, up 1.0% after 1 month and up 14.2% to date (from the $127.75 close on Jun 30, 2026).
MRK
Merck & Co., Inc.
Key Points
- Mary Ellen Coe bought 234 shares of Merck & Co., Inc. (NYSE:MRK) at $128.5 per share on June 30, 2026, totaling $30,069.
- Merck's stock traded near $128.5 on Wednesday, with a market cap of $317.4 billion and a P/E ratio of 36.2.
- Analysts from B of A Securities and Scotiabank maintained buy ratings with targets as high as $155.
Get $MRK trade alerts by text
We text you when insiders, Congress or big funds trade $MRK. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Merck & Co., Inc. alert may contain errors. Disclosures
On June 30, 2026, Mary Ellen Coe, an insider at Merck & Co., Inc. (NYSE:MRK), purchased 234 shares of the company. The shares were bought at $128.5 each, bringing the total transaction value to $30,069. This move adds to the interest in Merck from insiders.
Insider Buying and Selling at Merck & Co., Inc.
In addition to Mary Ellen Coe's purchase, several other insiders also bought shares. On the same day, Christine Seidman acquired 63 shares, and Surendralal Lanca bought 127 shares, both at $128.5 per share. Earlier, on May 29, Kathy Warden, Paul Rothman, and Christine Seidman purchased 1,853 shares each at a lower price of $118.72.
Merck & Co., Inc. Stock Down 11.5%
Shares of NYSE:MRK traded near $128.5 on Wednesday. Merck & Co., Inc. boasts a market capitalization of approximately $317.4 billion. The company has a P/E ratio of 36.2 and a forward P/E of 13.4, with a beta of 0.218, indicating lower volatility compared to the market. The stock's 52-week range is between $76.66 and $130.29, with a 50-day moving average of $116.12 and a 200-day moving average of $106.56.
Analysts Set New Price Targets
On June 30, 2026, B of A Securities maintained its buy rating on Merck, setting a price target of $141. Scotiabank also maintained a buy rating, with a target of $155. Earlier, on June 24, CICC initiated coverage with a buy rating and a $138 target. Overall, the consensus among analysts is a buy rating, with a mean price target of $130.39 across 28 opinions.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare company headquartered in Rahway, New Jersey. It operates in the drug manufacturing industry, providing pharmaceuticals for human health under well-known brands like Keytruda and Gardasil. The company also offers veterinary products and health management solutions. Led by CEO Robert M. Davis, Merck employs around 73,000 people worldwide.
Bottom Line
Mary Ellen Coe's purchase of Merck shares underscores ongoing insider interest in the company. Merck remains a significant player in the healthcare sector, with a strong market presence and a solid financial position. Investors keep a close eye on insider transactions as they can provide insights into the company's prospects. Remember, insider trading reports like these are backward-looking and reflect past actions, not necessarily current or future intentions.
Related Filing Alerts
Source: Coe Mary Ellen's Form 4 filing on $MRK (Jun 30, 2026). Find the original filing: MRK Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts